Yifan Pharmaceutical Co., Ltd.

Overview

Yifan Pharmaceutical Co., Ltd. is a leading pharmaceutical company in China, specializing in the research, development, production, and sales of innovative and generic pharmaceuticals. The company is dedicated to improving patient health outcomes through high-quality and accessible healthcare solutions.

Therapeutic areas

API / Drug Master Files

Yifan Pharmaceutical Co., Ltd. holds 63 active (74 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• TRIBENOSIDEActive2026-03-06
• DIFELIKEFALIN ACETATEActive2025-12-11
• AZACITIDINEActive2025-12-08
• CYTARABINEActive2025-11-26
• MELATONINActive2025-11-14
• DIAZOXIDEActive2025-10-30
• HYDROCORTISONE SODIUM SUCCINATEActive2025-09-22
• INSULIN DEGLUDECActive2025-06-15
• INSULIN ASPARTActive2025-06-04
• INSULIN GLARGINEActive2025-05-21
• SOMATROPINActive2025-04-28
• METHYLPREDNISOLONE PROCESS DActive2024-10-31
• FLUOCINOLONE ACETONIDEActive2024-09-28
• MOMETASONE FUROATE PRECESS BActive2024-08-30
• TRIAMCINOLONE ACETONIDEActive2024-04-29

Showing 15 of 74 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Yifan Pharmaceutical Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.